Intraarterial Milrinone Therapy for Delayed Cerebral Ischemia: Impact on Functional Dependency and Mortality
OSMANGAZİ JOURNAL OF MEDICINE · 09.06.2026 · 48 (4) · 616-630
DOI: 10.20515/otd.1803219 ↗Kurz gefasst
Fachartikel in der Zeitschrift OSMANGAZİ JOURNAL OF MEDICINE, online erschienen am 09.06.2026. Verfasst von Çağrı Elbir und 1 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Gefördert von: N/A.
Abstract (Originalsprache)
Delayed cerebral ischemia (DCI) secondary to aneurysmal subarachnoid hemorrhage (aSAH) is a major contributor to morbidity and mortality. In addition to oral nimodipine, normovolemia, and induced hypertension, intra-arterial (IA) administration of vasodilators has been employed in DCI treatment. One such agent is milrinone, a phosphodiesterase-3 inhibitor. This study aimed to evaluate the long-term clinical outcomes of IA milrinone administration. In this retrospective controlled study, 60 patients diagnosed with DCI following aSAH and treated at our institution between January 2023 and June 2024 were analyzed. Of these, 35 received only standard DCI therapy, and 25 underwent IA milrinone administration in addition to standard treatment. No serious or permanent complications related to milrinone administration were observed. Clinical and radiological data were compared, and outcomes were assessed using the modified Rankin scale at 6 months postoperatively. The hypothesis that IA milrinone reduces mortality and functional dependency was tested. The univariate analysis showed a non-significant trend toward reduced dependency in the milrinone group (OR: 0.94, p = 0.945), and similar findings were observed in the multivariate analysis (OR: 0.56, p = 0.594). A nonsignificant increase in mortality was observed in the IA therapy group. Age was the only independent predictor of survival. In conclusion, although IA milrinone therapy appears to be safe, it does not confer a statistically significant benefit in terms of long-term survival or functional outcomes in patients with DCI. Further large-scale prospective multicenter studies are required to validate these findings.
Förderung
- N/A
Zitieren
APA
Elbir, Ç., & Ülkü, G. (2026). Intraarterial Milrinone Therapy for Delayed Cerebral Ischemia: Impact on Functional Dependency and Mortality. OSMANGAZİ JOURNAL OF MEDICINE, 48(4), 616-630. https://doi.org/10.20515/otd.1803219
Vancouver
Elbir Ç, Ülkü G. Intraarterial Milrinone Therapy for Delayed Cerebral Ischemia: Impact on Functional Dependency and Mortality. OSMANGAZİ JOURNAL OF MEDICINE. 2026;48(4):616-630. doi:10.20515/otd.1803219
BibTeX
@article{Elbir2026,
author = {Elbir, Çağrı and Ülkü, Göktuğ},
title = {Intraarterial Milrinone Therapy for Delayed Cerebral Ischemia: Impact on Functional Dependency and Mortality},
journal = {OSMANGAZİ JOURNAL OF MEDICINE},
year = {2026},
volume = {48},
number = {4},
pages = {616--630},
doi = {10.20515/otd.1803219}
}
EUVIMED